TICATA 90 mg Film Coated Tablet

QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film coated tablet contains 90 mg Ticagrelor.
For the full list of excipients, see section "List of excipients".

PHARMACEUTICAL FORM
Film coated tablet (tablet).
Yellow, round, biconvex, film coated tablet with plain on one side and engraved 90 on the other

THERAPEUTIC INDICATIONS
TICATA 90 mg Film Coated Tablet is indicated for the following:
- **Acute Coronary Syndrome or a History of Myocardial Infarction**
  TICATA 90 mg Film Coated Tablet, co-administered with Acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non-ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
- **Acute Ischemic Stroke or Transient Ischemic Attack (TIA)**
  TICATA 90 mg Film Coated Tablet is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤ 5) or high-risk transient ischemic attack (TIA).

POSOLOGY AND METHOD OF ADMINISTRATION
Posology
- **Acute Coronary Syndrome or a History of Myocardial Infarction**
  TICATA 90 mg Film Coated Tablet treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily.
  Patients taking TICATA 90 mg Film Coated Tablet should also take ASA daily, unless specifically contraindicated. Following an initial dose of ASA, TICATA 90 mg Film Coated Tablet should be used with a maintenance dose of ASA of 75-150 mg.
  Treatment is recommended for up to 12 months unless discontinuation of TICATA 90 mg Film Coated Tablet is clinically indicated. Experience beyond 12 months is limited.
  Discontinuation of ASA may be considered after 3 months in patients with ACS who have undergone a percutaneous coronary intervention (PCI) procedure and have an increased risk of bleeding. In that case, Ticagrelor as single antiplatelet therapy should be continued for 9 months.
  In patients with Acute Coronary Syndromes (ACS), premature discontinuation with any antiplatelet therapy, including TICATA 90 mg Film Coated Tablet, could result in an increased risk of cardiovascular (CV) death, myocardial infarction (MI) or stroke due to the patient's underlying disease. Therefore, premature discontinuation of treatment should be avoided.
  In patients having an ACS event, the loading dose of 180 mg should be given as soon as possible regardless of any previous antiplatelet treatment.
- **Acute Ischemic Stroke or Transient Ischemic Attack (TIA)**
  Initiate treatment with a 180 mg loading dose of TICATA 90 mg Film Coated Tablet and then continue with 90 mg twice daily for up to 30 days. The treatment effect accrued early in the course of therapy.
  Use TICATA 90 mg Film Coated Tablet with a loading dose of ASA (300 to 325 mg) and a daily maintenance dose of ASA of 75 to 100 mg.
  Physicians who, desire to switch patients, with a prior ACS event, to TICATA 90 mg Film Coated Tablet should administer the first dose of TICATA 90 mg Film Coated Tablet 24 hours following the last dose of the other antiplatelet medication.

Missed dose
Lapses in therapy should also be avoided. A patient who misses a dose of TICATA 90 mg Film Coated Tablet should take only one 90 mg tablet (their next dose) at its scheduled time.

Special populations
Elderly
No dose adjustment is required in elderly.
Renal impairment
No dose adjustment is necessary for patients with renal impairment.
Hepatic impairment
Ticagrelor has not been studied in patients with severe hepatic impairment and its use in these patients is therefore contraindicated. Only limited information is available in patients with moderate hepatic impairment. Dose adjustment is not recommended, but Ticagrelor should be used with caution. No dose adjustment is necessary for patients with mild hepatic impairment.
Pediatric patients
The safety and efficacy of Ticagrelor in children below the age of 18 in the approved adult indication has not been established. There is no relevant use of Ticagrelor in children with sickle cell disease.

Method of administration
For oral use. TICATA 90 mg Film Coated Tablet can be taken with or without food. For patients who are unable to swallow the tablet(s) whole, the tablets can be crushed to a fine powder and mixed in half a glass of water and drunk immediately. The glass should be rinsed with a further half glass of water and the contents drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater). It is important to flush the nasogastric tube through with water after administration of the mixture.

CONTRAINDICATIONS
- Hypersensitivity to Ticagrelor or to any of the excipients of TICATA 90 mg Film Coated Tablet listed in section "List of excipients".
- Active pathological bleeding
- History of intracranial hemorrhage
- Severe hepatic impairment
- Co-administration of Ticagrelor with strong CYP3A4 inhibitors (e.g. Ketoconazole, Clarithromycin, Nefazodone, Ritonavir and Atazanavir), as co-administration may lead to a substantial increase in exposure to Ticagrelor.

SPECIAL WARNINGS AND PRECAUTIONS FOR USE
Special warnings
Bleeding risk
The use of Ticagrelor in patients at known increased risk for bleeding should be balanced against the benefit in terms of prevention of atherothrombotic events. If clinically indicated, Ticagrelor should be used with caution in the following patient groups:
- Patients with a propensity to bleed (e.g. due to recent trauma, recent surgery, coagulation disorders, active or recent gastrointestinal bleeding) or who are at increased risk of trauma. The use of Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage, and in patients with severe hepatic impairment.
- Patients with concomitant administration of medicinal products that may increase the risk of bleeding (e.g. non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and/or fibrinolytics) within 24 hours of Ticagrelor dosing.

Platelet transfusion did not reverse the antiplatelet effect of Ticagrelor in healthy volunteers and is unlikely to be of clinical benefit in patients with bleeding. Since co-administration of Ticagrelor with Desmopressin did not decrease template-bleeding time, Desmopressin is unlikely to be effective in managing clinical bleeding events.
Antifibrinolytic therapy (Aminocaproic acid or Tranexamic acid) and/or recombinant factor VIIa may increase hemostasis. Ticagrelor may be resumed after the cause of bleeding has been identified and controlled.
Patients treated for acute ischemic stroke or TIA
Patients at NIHSS > 5 and patients receiving thrombolysis were excluded and the use of TICATA 90 mg Film Coated Tablet in such patients is not recommended.

Precautions for use
Surgery
Patients should be advised to inform physicians and dentists that they are taking Ticagrelor before any surgery is scheduled and before any new medicinal product is taken.
Patients undergoing coronary artery bypass grafting (CABG), Ticagrelor had more bleeding than Clopidogrel when stopped within 1 day prior to surgery but a similar rate of major bleeds compared to Clopidogrel after stopping therapy 2 or more days before surgery. If a patient is to undergo elective surgery and antiplatelet effect is not desired, Ticagrelor should be discontinued 5 days prior to surgery.
Patients with prior ischaemic stroke
ACS patients with prior ischaemic stroke can be treated with Ticagrelor for up to 12 months.
Patients with history of MI with prior ischaemic stroke were not included. Therefore, in the absence of data, treatment beyond one year is not recommended in these patients.
Hepatic impairment
Use of Ticagrelor is contraindicated in patients with severe hepatic impairment. There is limited experience with Ticagrelor in patients with moderate hepatic impairment, therefore, caution is advised in these patients.
Patients at risk for bradycardic events
Holter ECG monitoring has shown an increased frequency of mostly asymptomatic ventricular pauses during treatment with Ticagrelor compared with Clopidogrel. Patients with an increased risk of bradycardic events (e.g. patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree AV block or bradycardic-related syncope) have been excluded from

the study evaluating the safety and efficacy of Ticagrelor as they may be at increased risk of developing bradyarrhythmias with Ticagrelor. Therefore, due to the limited clinical experience, Ticagrelor should be used with caution in these patients.
Bradyarrhythmic events, including 2nd and 3rd degree AV block, have however been reported in the post-marketing setting in patients with or without history of bradyarrhythmia, in most cases, shortly after initiation of treatment with Ticagrelor. Therefore, Ticagrelor should be used with caution and these patients should be closely monitored during the first few weeks on treatment.
In addition, caution should be exercised when administering Ticagrelor concomitantly with medicinal products known to induce bradycardia. However, no evidence of clinically significant adverse reactions was observed after concomitant administration with one or more medicinal products known to induce bradycardia (e.g. 96% beta blockers, 33% calcium channel blockers Diltiazem and Verapamil, and 4% Digoxin).
More patients had ventricular pauses ≥ 3 seconds with Ticagrelor than with Clopidogrel during the acute phase of their ACS. The increase in Holter-detected ventricular pauses with Ticagrelor was higher in patients with chronic heart failure (CHF) than in the overall study population during the acute phase of ACS, but not at one month with Ticagrelor or compared to Clopidogrel. There were no adverse clinical consequences associated with this imbalance (including syncope or pacemaker insertion) in this patient population.
Dyspnea
Dyspnea was reported in patients treated with Ticagrelor. Dyspnea is usually mild to moderate in intensity and often resolves without need for treatment discontinuation. Patients with asthma/chronic obstructive pulmonary disease (COPD) may have an increased absolute risk of experiencing dyspnea with Ticagrelor. Ticagrelor should be used with caution in patients with history of asthma and/or COPD. The mechanism has not been elucidated. If a patient reports new, prolonged or worsened dyspnea this should be investigated fully and if not tolerated, treatment with Ticagrelor should be stopped.
Central sleep apnea
Central sleep apnea including Cheyne-Stokes respiration has been reported in the post-marketing setting in patients taking Ticagrelor. If central sleep apnea is suspected, further clinical assessment should be considered.
Creatinine elevations
Creatinine levels may increase during treatment with Ticagrelor. The mechanism has not been elucidated. Renal function should be checked according to routine medical practice. In patients with ACS, it is recommended that renal function is also checked one month after initiating the treatment with Ticagrelor, paying special attention to patients ≥ 75 years, patients with moderate/severe renal impairment and those receiving concomitant treatment with an angiotensin receptor blocker (ARB).
Uric acid increase
Hyperuricemia may occur during treatment with Ticagrelor. Caution is advised in patients with history of hyperuricemia or gouty arthritis. As a precautionary measure, the use of Ticagrelor in patients with uric acid nephropathy is discouraged.
Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely with the use of Ticagrelor. It is characterized by thrombocytopenia and microangiopathic hemolytic anemia associated with either neurological findings, renal dysfunction or fever. TTP is a potentially fatal condition requiring prompt treatment including plasmapheresis.
Interference with platelet function tests to diagnose heparin induced thrombocytopenia (HIT)
In the heparin induced platelet activation (HIPA) test used to diagnose HIT, anti-platelet factor 4/heparin antibodies in patient serum activate platelets of healthy donors in the presence of heparin. False negative results in a platelet function test (to include, but may not be limited to the HIPA test) for HIT have been reported in patients administered Ticagrelor. This is related to inhibition of the P2Y12-receptor on the healthy donor platelets in the test by Ticagrelor in the patient's sera/plasma. Information on concomitant treatment with Ticagrelor is required for interpretation of HIT platelet function tests.
In patients who have developed HIT, the benefit-risk of continued treatment with Ticagrelor should be assessed, taking both the prothrombotic state of HIT and the increased risk of bleeding with concomitant anticoagulant and Ticagrelor treatment into consideration.
Other
Based on a relationship observed between maintenance ASA dose and relative efficacy of Ticagrelor compared to Clopidogrel, co-administration of Ticagrelor and high maintenance dose ASA (> 300 mg) is not recommended.
Sodium
TICATA 90 mg Film Coated Tablet contain less than 1 mmol Sodium (23 mg) per dose, i.e. is essentially 'Sodium-free'.

INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION
Ticagrelor is primarily a CYP3A4 substrate and a mild inhibitor of CYP3A4. Ticagrelor is also a P-glycoprotein P-gp substrate and a weak P-gp inhibitor and may increase the exposure of P-gp substrates. Ticagrelor is a breast cancer resistance protein (BRCP) inhibitor.
Effects of medicinal and other products on Ticagrelor
CYP3A4 inhibitors
- *Strong CYP3A4 inhibitors* – Co-administration of Ketoconazole with Ticagrelor increased the Ticagrelor C_{max} and AUC equal to 2.4-fold and 7.3-fold, respectively. The C_{max} and AUC of the active metabolite were reduced by 89% and 56%, respectively. Other strong inhibitors of CYP3A4 (Clarithromycin, Nefazodone, Ritonavir, and Atazanavir) would be expected to have similar effects and therefore concomitant use of strong CYP3A4 inhibitors with Ticagrelor is contraindicated.
- *Moderate CYP3A4 inhibitors* – Co-administration of Diltiazem with Ticagrelor increased the Ticagrelor C_{max} by 69% and AUC to 2.7-fold and decreased the active metabolite C_{max} by 38% and AUC was unchanged. There was no effect of Ticagrelor on Diltiazem plasma levels. Other moderate CYP3A4 inhibitors (e.g. Amprenavir, Aprepitant, Erythromycin and Fluconazole) would be expected to have a similar effect and can as well be co-administered with Ticagrelor.
- A 2-fold increase of Ticagrelor exposure was observed after daily consumption of large quantities of grapefruit juice (3 x 200 mL). This magnitude of increased exposure is not expected to be clinically relevant to most patients.

CYP3A inducers
Co-administration of Rifampicin with Ticagrelor decreased Ticagrelor C_{max} and AUC by 73% and 86%, respectively. The C_{max} of the active metabolite was unchanged and the AUC was decreased by 46%, respectively. Other CYP3A inducers (e.g. Phenytoin, Carbamazepine and Phenobarbital) would be expected to decrease the exposure to Ticagrelor as well. Co-administration of Ticagrelor with potent CYP3A inducers may decrease exposure and efficacy of Ticagrelor, therefore, their concomitant use with Ticagrelor is discouraged.
Cyclosporine (P-gp and CYP3A inhibitor)
Co-administration of cyclosporine (600 mg) with Ticagrelor increased Ticagrelor C_{max} and AUC equal to 2.3-fold and 2.8-fold, respectively. The AUC of the active metabolite was increased by 32% and C_{max} was decreased by 15% in the presence of cyclosporine.
No data are available on concomitant use of Ticagrelor with other active substances that also are potent P-gp inhibitors and moderate CYP3A4 inhibitors (e.g. Verapamil, Quinidine) that also may increase Ticagrelor exposure. If the association cannot be avoided, their concomitant use should be made with caution.
Others
Clinical pharmacology interaction studies showed that co-administration of Ticagrelor with Heparin, Enoxaparin and ASA or Desmopressin did not have any effect on the pharmacokinetics of Ticagrelor or the active metabolite or on ADP-induced platelet aggregation compared with Ticagrelor alone. If clinically indicated, medicinal products that alter hemostasis should be used with caution in combination with Ticagrelor.
A delayed and decreased exposure to oral $P2Y_{12}$ inhibitors, including Ticagrelor and its active metabolite, has been observed in patients with ACS treated with morphine (35% reduction in Ticagrelor exposure). This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced Ticagrelor efficacy in patients co-administered Ticagrelor and morphine. In patients with ACS, in whom morphine cannot be withheld and fast $P2Y_{12}$ inhibition is deemed crucial, the use of a parenteral $P2Y_{12}$ inhibitor may be considered.
Effects of Ticagrelor on other medicinal products
Medicinal products metabolized by CYP3A4
- *Simvastatin* – Co-administration of Ticagrelor with Simvastatin increased Simvastatin C_{max} by 81% and AUC by 56% and increased Simvastatin acid C_{max} by 64% and AUC by 52% with some individual increases equal to 2- to 3-fold. Co-administration of Ticagrelor with doses of Simvastatin exceeding 40 mg daily could cause adverse effects of Simvastatin and should be weighed against potential benefits. There was no effect of Simvastatin on Ticagrelor plasma levels. Ticagrelor may have similar effect on Lovastatin. The concomitant use of Ticagrelor with doses of Simvastatin or Lovastatin greater than 40 mg is not recommended.
- *Atorvastatin* – Co-administration of Atorvastatin and Ticagrelor increased Atorvastatin acid C_{max} by 23% and AUC by 36%. Similar increases in AUC and C_{max} were observed for all Atorvastatin acid metabolites. These increases are not considered clinically significant.
- A similar effect on other statins metabolized by CYP3A4 cannot be excluded. Patients receiving Ticagrelor took a variety of statins, with no concern of an association with statin safety among the 93% taking these medicinal products.

Ticagrelor is a mild CYP3A4 inhibitor. Co-administration of Ticagrelor and CYP3A4 substrates with narrow therapeutic indices (i.e. Cisapride or Ergot alkaloids) is not recommended, as Ticagrelor may increase the exposure to these medicinal products.
P-gp substrates (including Digoxin, Cyclosporine)
Concomitant administration of Ticagrelor increased the Digoxin C_{max} by 75% and AUC by 28%. The mean trough Digoxin levels were increased about 30% with Ticagrelor co-administration with some individual maximum increases to 2-fold. In the presence of Digoxin, the C_{max} and AUC of Ticagrelor and its active metabolite were not affected. Therefore, appropriate clinical and/or laboratory monitoring is recommended when giving narrow therapeutic index P-gp dependent medicinal products like Digoxin concomitantly with Ticagrelor.
There was no effect of Ticagrelor on cyclosporine blood levels. Effect of Ticagrelor on other P-gp substrates has not been studied.
Medicinal products metabolized by CYP2C9
Co-administration of Ticagrelor with Tolbutamide resulted in no change in the plasma levels of either medicinal product, which suggest that Ticagrelor is not a CYP2C9 inhibitor and unlikely to alter the CYP2C9 mediated metabolism of medicinal products like Warfarin and Tolbutamide.
Rosuvastatin (BCRP substrate)
Ticagrelor has been shown to increase Rosuvastatin concentrations, which may result in increased risk of myopathy. Consideration should be given to the benefits or prevention of major adverse cardiovascular events by use of Rosuvastatin and the risks with increased Rosuvastatin plasma concentrations.

Oral contraceptives
Co-administration of Ticagrelor and Levonorgestrel and Ethinyl estradiol increased Ethinyl estradiol exposure approximately 20% but did not alter the pharmacokinetics of Levonorgestrel. No clinically relevant effect on oral contraceptive efficacy is expected when Levonorgestrel and Ethinyl estradiol are co-administered with Ticagrelor.
Medicinal products known to induce bradycardia
Due to observations of mostly asymptomatic ventricular pauses and bradycardia, caution should be exercised when administering Ticagrelor concomitantly with medicinal products known to induce bradycardia. However, no evidence of clinically significant adverse reactions was observed in the PLATO trial after concomitant administration with one or more medicinal products known to induce bradycardia (e.g. 96% beta blockers, 33% calcium channel blockers Diltiazem and Verapamil, and 4% Digoxin).
Other concomitant therapy
Ticagrelor was commonly administered with ASA, proton pump inhibitors, statins, beta-blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers as needed for concomitant conditions for long-term and also Heparin, low molecular weight Heparin and intravenous GpIIb/IIIa inhibitors for short durations. No evidence of clinically significant adverse interactions with these medicinal products was observed.
Co-administration of Ticagrelor with Heparin, Enoxaparin or Desmopressin had no effect on activated partial thromboplastin time (aPTT), activated coagulation time (ACT) or factor Xa assays. However, due to potential pharmacodynamic interactions, caution should be exercised with the concomitant administration of Ticagrelor with medicinal products known to alter hemostasis.
Due to reports of cutaneous bleeding abnormalities with SSRIs (e.g. Paroxetine, Sertraline and Citalopram), caution is advised when administering SSRIs with Ticagrelor as this may increase the risk of bleeding.

FERTILITY, PREGNANCY AND LACTATION
Women of childbearing potential
Women of childbearing potential should use appropriate contraceptive measures to avoid pregnancy during Ticagrelor therapy.
Pregnancy
There are no or limited amount of data from the use of Ticagrelor in pregnant women. Studies in animals have shown reproductive toxicity. Ticagrelor is not recommended during pregnancy.
Breastfeeding
Available pharmacodynamic/toxicological data in animals have shown excretion of Ticagrelor and its active metabolites in milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from Ticagrelor therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Fertility
Ticagrelor had no effect on male or female fertility in animals.

EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
Ticagrelor has no or negligible influence on the ability to drive and use machines. During treatment with Ticagrelor, dizziness and confusion have been reported. Therefore, patients who experience these symptoms should be cautious while driving or using machines.

UNDESIRABLE EFFECTS
The following adverse reactions have been identified following studies or have been reported in post-marketing experience with Ticagrelor (Table 1).
Adverse reactions are listed by MedDRA System Organ Class (SOC). Within each SOC the adverse reactions are ranked by frequency categories. Frequency categories are defined according to the following conventions: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data).

Table 1 - Adverse reactions by frequency and system organ class (SOC)

SOC	Very Common	Common	Uncommon	Not Known
Neoplasms benign, malignant and unspecified (including cysts and polyps)			Tumor bleedings[a]	
Blood and lymphatic system disorders	Blood disorder bleedings[b]			Thrombotic Thrombocytopenic Purpura[c]
Immune system disorders			Hypersensitivity including angioedema[c]	
Metabolism and nutrition disorders	Hyperuricemia[d]	Gout/Gouty arthritis		
Psychiatric disorders			Confusion	
Nervous system disorders		Dizziness Syncope Headache	Intracranial hemorrhage[m]	
Eye disorders			Eye hemorrhage[e]	
Ear and labyrinth disorders		Vertigo	Ear hemorrhage	
Vascular disorders		Hypotension		
Cardiac disorders				Bradyarrhythmia[c] AV block (2nd and 3rd degree)[c]
Respiratory, thoracic and mediastinal disorders	Dyspnea	Respiratory system bleedings[f]		
Gastrointestinal disorders		Gastrointestinal hemorrhage[f] Diarrhea, Nausea, Dyspepsia, Constipation	Retroperitoneal hemorrhage	
Skin and subcutaneous tissue disorders		Subcutaneous or dermal bleeding[h], Rash, Pruritus		
Musculoskeletal and connective tissue disorders			Muscular bleeding[i]	
Renal and urinary disorders		Urinary tract bleedings[j]		
Reproductive system and breast disorders			Reproductive system bleedings[k]	
Investigations		Blood creatinine increased[d]		
Injury, poisoning and procedural complications		Post procedural hemorrhage, Traumatic bleedings[l]		

AV = atroventricular
a e.g. bleeding from bladder cancer, gastric cancer, colon cancer
b e.g. increased tendency to bruise, spontaneous hematoma, hemorrhagic diathesis
c Identified in post-marketing experience
d Frequencies derived from lab observations (Uric acid increases to > upper limit of normal from baseline below or within reference range. Creatinine increases of > 50% from baseline.) and not crude adverse event report frequency.
e e.g. conjunctival, retinal, intraocular bleeding
f e.g. epistaxis, hemoptysis
g e.g. gingival bleeding, rectal hemorrhage, gastric ulcer hemorrhage
h e.g. ecchymosis, skin hemorrhage, petechiae
i e.g. hemarthrosis, muscle hemorrhage
j e.g. hematuria, cystitis hemorrhagic
k e.g. vaginal hemorrhage, hematospermia, postmenopausal hemorrhage
l e.g. contusion, traumatic hematoma, traumatic hemorrhage
m i.e. spontaneous procedure related or traumatic intracranial hemorrhage

Description of selected adverse reactions
Bleeding
Bleeding findings in PLATO
Overall outcome of bleeding rates in the PLATO study are shown in Table 2.

Table 2 - Analysis of overall bleeding events, Kaplan-Meier estimates at 12 months (PLATO)

	Ticagrelor 90 mg twice daily N = 9235	Clopidogrel N = 9186	p-value*
PLATO Total Major	11.6	11.2	0.4336
PLATO Major Fatal/Life-Threatening	5.8	5.8	0.6988
Non-CABG PLATO Major	4.5	3.8	0.0264
Non-Procedural PLATO Major	3.1	2.3	0.0058
PLATO Total Major + Minor	16.1	14.6	0.0084
Non-Procedural PLATO Major + Minor	5.9	4.3	< 0.0001
TIMI-defined Major	7.9	7.7	0.5669
TIMI-defined Major + Minor	11.4	10.9	0.3272

Bleeding category definitions*:*
Major Fatal/Life-threatening Bleed: Clinically apparent with > 50 g/L decrease in hemoglobin or ≥ 4 red cell units transfused; or fatal; or intracranial; or intrapericardial with cardiac tamponade; or with hypovolemic shock or severe hypotension requiring pressors or surgery
Major Other: Clinically apparent with 30 - 50 g/L decrease in hemoglobin or 2 - 3 red cell units transfused; or significantly disabling
Minor Bleed: Requires medical intervention to stop or treat bleeding
TIMI Major Bleed: Clinically apparent with > 50 g/L decrease in hemoglobin or intracranial hemorrhage
TIMI Minor Bleed: Clinically apparent with 30 - 50 g/L decrease in hemoglobin.
*p-value calculated from Cox proportional hazards model with treatment group as the only explanatory variable

Ticagrelor and Clopidogrel did not differ in rates of PLATO Major Fatal/Life-threatening bleeding, PLATO total Major bleeding, TIMI Major bleeding, or TIMI Minor bleeding (Table 2). However, more PLATO combined Major + Minor bleeding occurred with Ticagrelor compared with Clopidogrel. Few patients in PLATO had fatal bleeds: 20 (0.2%) for Ticagrelor and 23 (0.3%) for Clopidogrel (*see section Special Warnings and Precautions for Use*).

Age, sex, weight, race, geographic region, concurrent conditions, concomitant therapy, and medical history, including a previous stroke or transient ischemic attack, all did not predict either overall or non-procedural PLATO Major bleeding. Thus, no particular group was identified at risk for any subset of bleeding.

CABG-related bleeding: In PLATO, 42% of the 1584 patients (12% of cohort) who underwent coronary artery bypass graft (CABG) surgery had a PLATO Major Fatal/Life-threatening bleeding with no difference between treatment groups. Fatal CABG bleeding occurred in 6 patients in each treatment group (*see section Special Warnings and Precautions for Use*).

Non-CABG related bleeding and non-procedural related bleeding: Ticagrelor and Clopidogrel did not differ in non-CABG PLATO-defined Major Fatal/Life-threatening bleeding, but PLATO-defined Total Major, TIMI Major, and TIMI Major + Minor bleeding were more common with Ticagrelor. Similarly, when removing all procedure related bleeds, more bleeding occurred with ticagrelor than with Clopidogrel (Table 2). Discontinuation of treatment due to non-procedural bleeding was more common for Ticagrelor (2.9%) than for Clopidogrel (1.2%; p < 0.001).

Intracranial bleeding: There were more intracranial non-procedural bleeds with Ticagrelor (n = 27 bleeds in 26 patients, 0.3%) than with Clopidogrel (n = 14 bleeds, 0.2%), of which 11 bleeds with Ticagrelor and 1 with Clopidogrel were fatal. There was no difference in overall fatal bleeds.

Bleeding findings in PEGASUS
Overall outcome of bleeding events in the PEGASUS study are shown in Table 3.

Table 3 - Analysis of overall bleeding events, Kaplan-Meier estimates at 36 months (PEGASUS)

	Ticagrelor 60 mg twice daily + ASA N = 6958		ASA alone N = 6996	
Safety Endpoints	**KM%**	**Hazard Ratio (95% CI)**	**KM%**	**p-value**
TIMI-defined bleeding categories				
TIMI Major	2.3	2.32 (1.68, 3.21)	1.1	< 0.0001
Fatal	0.3	1.00 (0.44, 2.27)	0.3	1.0000
ICH	0.6	1.33 (0.77, 2.31)	0.5	0.3130
Other TMI Major	1.6	3.61 (2.31, 5.65)	0.5	< 0.0001
TIMI Major or Minor	3.4	2.54 (1.93, 3.35)	1.4	< 0.0001
TIMI Major or Minor or Requiring medical attention	16.6	2.64 (2.35, 2.97)	7.0	< 0.0001
PLATO-defined bleeding categories				
PLATO Major	3.5	2.57 (1.95, 3.37)	1.4	< 0.0001
Fatal/Life-threatening	2.4	2.38 (1.73, 3.26)	1.1	< 0.0001
Other PLATO Major	1.1	3.37 (1.95, 5.83)	0.3	< 0.0001
PLATO Major or Minor	15.2	2.71 (2.40, 3.08)	6.2	< 0.0001

Bleeding category definitions:
TIMI Major: Fatal bleeding, OR any intracranial bleeding, OR clinically overt signs of hemorrhage associated with a drop in hemoglobin (Hgb) of ≥ 50 g/L, or when Hgb is not available, a fall in hematocrit (Hct) of 15%.
Fatal: A bleeding event that directly led to death within 7 days.
ICH: Intracranial hemorrhage.
Other TIMI Major: Non-fatal non-ICH TIMI Major bleeding.
TIMI Minor: Clinically apparent with 30 - 50 g/L decrease in hemoglobin.
TIMI Requiring medical attention: Requiring intervention, OR leading to hospitalization, OR prompting evaluation.
PLATO Major Fatal/life-threatening: Fatal bleeding, OR any intracranial bleeding, OR intrapericardial with cardiac tamponade, OR with hypovolemic shock or severe hypotension requiring pressors/inotropes or surgery OR clinically apparent with > 50 g/L decrease in hemoglobin or ≥ 4 red cell units transfused.
PLATO Major Other: Significantly disabling, OR clinically apparent with 30-50 g/L decrease in hemoglobin, OR 2 - 3 red cell units transfused.
PLATO Minor: Requires medical intervention to stop or treat bleeding.

In PEGASUS, TIMI Major bleeding for Ticagrelor 60 mg twice daily was higher than for ASA alone. No increased bleeding risk was seen for fatal bleeding and only a minor increase was observed in intracranial hemorrhages, as compared to ASA therapy alone. There were few fatal bleeding events in the study, 11 (0.3%) for Ticagrelor 60 mg and 12 (0.3%) for ASA therapy alone. The observed increased risk of TIMI Major bleeding with Ticagrelor 60 mg was primarily due to a higher frequency of Other TIMI Major bleedings driven by events in the gastrointestinal SOC.

Increased bleeding patterns similar to TIMI Major were seen for TIMI Major or Minor and PLATO Major and PLATO Major or Minor bleeding categories (see Table 3). Discontinuation of treatment due to bleeding was more common with Ticagrelor 60 mg compared to ASA therapy alone (6.2% and 1.5%, respectively). The majority of these bleedings were of less severity (classified as TIMI Requiring medical attention), e.g. epistaxis, bruising and hematomas.

The bleeding profile of Ticagrelor 60 mg was consistent across multiple pre-defined subgroups (e.g. by age, gender, weight, race, geographic region, concurrent conditions, concomitant therapy and medical history) for TIMI Major, TIMI Major or Minor and PLATO Major bleeding events.

Intracranial bleeding: Spontaneous ICHs were reported in similar rates for Ticagrelor 60 mg and ASA therapy alone (n = 13, 0.2% in both treatment groups). Traumatic and procedural ICHs showed a minor increase with Ticagrelor 60 mg treatment, (n = 15, 0.2%) compared with ASA therapy alone (n = 10, 0.1%). There were 6 fatal ICHs with Ticagrelor 60 mg and 5 fatal ICHs with ASA therapy alone. The incidence of intracranial bleeding was low in both treatment groups given the significant comorbidity and CV risk factors of the population under study.

Bleeding findings in THALES
Overall outcome of bleeding events in the THALES study are shown in Table 4.

Table 4 - Analysis of bleeding events, Kaplan-Meier estimate of bleeding rates by treatment at 30 days (THALES)[a]

	Ticagrelor 90 mg twice daily with ASA N = 5523			ASA alone N = 5493		
Safety Endpoints	**Patient with events**	**KM%**	**Hazard Ratio (95% CI)**	**Patients with events**	**KM%**	***p*-value**
GUSTO-defined bleeding categories						
GUSTO Severe	28 (0.5%)	0.5%	3.99 (1.74, 9.14)	7 (0.1%)	0.1%	0.001
GUSTO Severe or Moderate	36 (0.7%)	0.6%	3.27 (1.67, 6.43)	11 (0.2%)	0.2%	< 0.001

Bleeding category definitions:
GUSTO Severe: Any one of the following: fatal bleeding, intracranial bleeding (excluding asymptomatic hemorrhagic transformations of ischemic brain infarctions and excluding microhemorrhages <10 mm evident only on gradient-echo magnetic resonance imaging), bleeding that caused hemodynamic compromise requiring intervention (e.g. systolic blood pressure < 90 mm Hg that required blood or fluid replacement, or vasopressor/inotropic support, or surgical intervention).
GUSTO Moderate: Bleeding requiring transfusion of whole blood or packed red blood cells without hemodynamic compromise (as defined above).
[a]Full analysis set - intention-to-treat analysis: included all patients randomized irrespective of their protocol adherence and continued participation in the study.

In THALES, the rate of GUSTO Severe bleeding for Ticagrelor 90 mg twice daily in combination with ASA was higher than for ASA alone. A similar bleeding pattern was observed for the GUSTO Severe or Moderate bleeding category (see Table 4). Due to the low number of GUSTO Severe bleeding events, no conclusion can be drawn regarding bleeding risk across subgroups. Discontinuation of treatment due to bleeding was more common with Ticagrelor 90 mg with ASA compared to ASA therapy alone (2.9% and 0.6%, respectively).
Intracranial bleeding and fatal bleeding: In total, there were 21 intracranial hemorrhages (ICHs) (19 spontaneous, 1 traumatic, 1 procedural) for Ticagrelor 90 mg with ASA and 6 ICHs (3 spontaneous, 2 traumatic, 1 procedural) for ASA alone. Fatal bleedings occurred in 11 patients (10 fatal ICHs, 1 fatal gastro-intestinal bleed) for Ticagrelor 90 mg with ASA and in 2 patients (2 fatal ICHs) for ASA alone.

Dyspnea
Dyspnea, a sensation of breathlessness, is reported by patients treated with Ticagrelor. In PLATO, dyspnea adverse events (AEs) (dyspnea, dyspnea at rest, dyspnea exertional, dyspnea paroxysmal nocturnal and nocturnal dyspnea), when combined, was reported by 13.8% of patients treated with Ticagrelor and by 7.8% of patients treated with Clopidogrel. In 2.2% of patients taking Ticagrelor and by 0.6% taking Clopidogrel investigators considered the dyspnea causally related to treatment in the PLATO study and few were serious (0.14% Ticagrelor; 0.02% Clopidogrel), (*see section Special Warnings and Precautions for Use*). Most reported symptoms of dyspnea were mild to moderate in intensity, and most were reported as a single episode early after starting treatment.

Compared with Clopidogrel, patients with asthma/COPD treated with Ticagrelor may have an increased risk of experiencing non-serious dyspnea (3.29% Ticagrelor versus 0.53% Clopidogrel) and serious dyspnea (0.38% Ticagrelor versus 0.00% Clopidogrel). In absolute terms, this risk was higher than in the overall PLATO population. Ticagrelor should be used with caution in patients with history of asthma and/or COPD (*see section Special Warnings and Precautions for Use*).

About 30% of episodes resolved within 7 days. PLATO included patients with baseline congestive heart failure, chronic obstructive pulmonary disease, or asthma; these patients, and the elderly, were more likely to report dyspnea. For Ticagrelor, 0.9% of patients discontinued study drug because of dyspnea compared with 0.1% taking Clopidogrel. The higher incidence of dyspnea with Ticagrelor is not associated with new or worsening heart or lung disease (*see section Special Warnings and Precautions for Use*). Ticagrelor does not affect test of pulmonary function.

In PEGASUS dyspnea was reported in 14.2% of patients taking Ticagrelor 60 mg twice daily and in 5.5% of patients taking ASA alone. As in PLATO, most reported dyspnea was mild to moderate in intensity (*see section Special Warnings and Precautions for Use*). Patients who reported dyspnea tended to be older and more frequently had dyspnea, COPD or asthma at baseline.

In THALES, dyspnea led to study drug discontinuation in 1.0% and 0.2% of patients taking Ticagrelor 90 mg in combination with ASA vs. ASA alone, respectively.

Investigations
Uric acid elevations: In PLATO, serum uric acid concentration increased to more than upper limit of normal in 22% of patients receiving Ticagrelor compared to 13% of patients receiving Clopidogrel. The corresponding numbers in PEGASUS were 9.1%, 8.8% and 5.5% for Ticagrelor 90 mg, 60 mg and placebo, respectively. Mean serum uric acid concentration increased approximately 15% with Ticagrelor compared to approximately 7.5% with Clopidogrel and after treatment was stopped, decreased to approximately 7% on Ticagrelor but with no decrease observed for Clopidogrel. In PEGASUS, a reversible increase in mean serum uric acid levels of 6.3% and 5.6% was found for Ticagrelor 90 mg and 60 mg, respectively, compared to a 1.5% decrease in the placebo group. In PLATO, the frequency of gouty arthritis was 0.2% for Ticagrelor vs. 0.1% for Clopidogrel. The corresponding numbers for gout/gouty arthritis in PEGASUS were 1.6%, 1.5% and 1.1% for Ticagrelor 90 mg, 60 mg and placebo, respectively.

OVERDOSE
Ticagrelor is well tolerated in single doses up to 900 mg. Gastrointestinal toxicity was dose-limiting in a single ascending dose study. Other clinically meaningful adverse reactions which may occur with overdose include dyspnea and ventricular pauses.
In the event of an overdose, the above potential adverse reactions could occur and ECG monitoring should be considered.
There is currently no known antidote to reverse the effects of Ticagrelor, and Ticagrelor is not dialyzable. Treatment of overdose should follow local standard medical practice. The expected effect of excessive Ticagrelor dosing is prolonged duration of bleeding risk associated with platelet inhibition. Platelet transfusion is unlikely to be of clinical benefit in patients with bleeding. If bleeding occurs appropriate supportive measures should be taken.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic Properties
Mechanism of action
TICATA 90 mg Film Coated Tablet contains Ticagrelor, a member of the chemical class cyclopentyltriazolopyrimidines (CPTP), which is an oral, direct acting, selective and reversibly binding P2Y12 receptor antagonist that prevents ADP-mediated P2Y12 dependent platelet activation and aggregation. Ticagrelor does not prevent ADP binding, but when bound to the P2Y12 receptor prevents ADP-induced signal transduction. Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function has been shown to reduce the risk of CV events such as death, MI or stroke.
Ticagrelor also increases local endogenous adenosine levels by inhibiting equilibrative nucleoside transporter-1 (ENT-1).
Ticagrelor has been documented to augment the following adenosine-induced effects in healthy subjects and in patients with ACS: vasodilation (measured by coronary blood flow increases in healthy volunteers and ACS patients; headache), inhibition of platelet function (in human whole blood *in vitro*) and dyspnea. However, a link between the observed increases in adenosine and clinical outcomes (e.g. morbidity mortality) has not been clearly elucidated.
Pharmacodynamics Effects
Onset of action
In patients with stable coronary artery disease (CAD) on ASA, Ticagrelor demonstrates a rapid onset of pharmacological effect as demonstrated by a mean inhibition of platelet aggregation (IPA) for Ticagrelor at 0.5 hours after 180 mg loading dose of about 41%, with the maximum IPA effect of 89% by 2-4 hours post dose, and maintained between 2-8 hours. 90% of patients had final extent IPA > 70% by 2 hours post dose.
Offset of action
If a CABG procedure is planned, Ticagrelor bleeding risk is increased compared to Clopidogrel when discontinued within less than 96 hours prior to procedure.
Switching data
Switching from Clopidogrel 75 mg to Ticagrelor 90 mg twice daily results in an absolute IPA increase of 26.4% and switching from Ticagrelor to Clopidogrel results in an absolute IPA decrease of 24.5%. Patients can be switched from Clopidogrel to Ticagrelor without any interruption of antiplatelet effect.

Pharmacokinetic Properties
Ticagrelor demonstrates linear pharmacokinetics and exposure to Ticagrelor and the active metabolite (AR-C124910XX) are approximately dose proportional up to 1260 mg.
Absorption
Absorption of Ticagrelor is rapid with a median t_{max} of approximately 1.5 hours. The formation of the major circulating metabolite AR-C124910XX (also active) from Ticagrelor is rapid with a median t_{max} of approximately 2.5 hours.
The mean absolute bioavailability of Ticagrelor was estimated to be 36%. Ingestion of a high-fat meal resulted in a 21% increase in Ticagrelor AUC and 22% decrease in the active metabolite C_{max} but had no effect on Ticagrelor C_{max} or the AUC of the active metabolite. These small changes are considered of minimal clinical significance; therefore, Ticagrelor can be given with or without food. Ticagrelor as well as the active metabolite are P-gp substrates.
Ticagrelor as crushed tablets mixed in water, given orally or administered through a nasogastric tube into the stomach, has a comparable bioavailability to whole tablets with regards to AUC and C_{max} for Ticagrelor and the active metabolite. Initial exposure (0.5 and 1 hour post-dose) from crushed Ticagrelor tablets mixed in water was higher compared to whole tablets, with a generally identical concentration profile thereafter (2 to 48 hours).

Distribution
The steady state volume of distribution of Ticagrelor is 87.5 L. Ticagrelor and the active metabolite is extensively bound to human plasma protein (> 99.0%).
Biotransformation
CYP3A4 is the major enzyme responsible for Ticagrelor metabolism and the formation of the active metabolite and their interactions with other CYP3A substrates ranges from activation through to inhibition.
The major metabolite of Ticagrelor is AR-C124910XX, which is also active as assessed by *in vitro* binding to the platelet P2Y12 ADP-receptor. The systemic exposure to the active metabolite is approximately 30-40% of that obtained for Ticagrelor.
Elimination
The primary route of Ticagrelor elimination is via hepatic metabolism. When radio labelled Ticagrelor is administered, the mean recovery of radioactivity is approximately 84% (57.8% in feces, 26.5% in urine). Recoveries of Ticagrelor and the active metabolite in urine were both less than 1% of the dose. The primary route of elimination for the active metabolite is most likely via biliary secretion. The mean $t_{1/2}$ was approximately 7 hours for Ticagrelor and 8.5 hours for the active metabolite.
Special population
Elderly
Higher exposures to Ticagrelor (approximately 25% for both C_{max} and AUC) and the active metabolite were observed in elderly (≥ 75 years) ACS patients compared to younger patients by the population pharmacokinetic analysis. These differences are not considered clinically significant.
Pediatric population
Limited data are available in children with sickle cell disease.
Gender
Higher exposures to Ticagrelor and the active metabolite were observed in women compared to men. These differences are not considered clinically significant.
Ethnicity
Patients of Asian descent have a 39% higher mean bioavailability compared to Caucasian patients. Patients self-identified as Black had an 18% lower bioavailability of Ticagrelor compared to Caucasian patients. In clinical pharmacology studies, the exposure (C_{max} and AUC) to Ticagrelor in Japanese subjects was approximately 40% (20% after adjusting for body weight) higher compared to that in Caucasians. The exposure in patients self-identified as Hispanic or Latino was similar to that in Caucasians.
Renal impairment
Exposure to Ticagrelor was approximately 20% lower and exposure to the active metabolite was approximately 17% higher in patients with severe renal impairment (creatinine clearance < 30 mL/min) compared to subjects with normal renal function.
In patients with end stage renal disease on hemodialysis AUC and C_{max} of Ticagrelor 90 mg administered on a day without dialysis were 38% and 51% higher compared to subjects with normal renal function. A similar increase in exposure was observed when Ticagrelor was administered immediately prior to dialysis (49% and 61%, respectively) showing that Ticagrelor is not dialyzable. Exposure of the active metabolite increased to a lesser extent (AUC 13-14% and C_{max} 17-36%). The inhibition of platelet aggregation (IPA) effect of Ticagrelor was independent of dialysis in patients with end stage renal disease and similar to subjects with normal renal function.
Hepatic impairment
C_{max} and AUC for Ticagrelor were 12% and 23% higher in patients with mild hepatic impairment compared to matched healthy subjects, respectively, however, the IPA effect of Ticagrelor was similar between the two groups. No dose adjustment is needed for patients with mild hepatic impairment. Ticagrelor has not been studied in patients with severe hepatic impairment and there is no pharmacokinetic information in patients with moderate hepatic impairment. In patients that had moderate or severe elevation in one or more liver function tests at baseline, Ticagrelor plasma concentrations were on average similar or slightly higher as compared to those without baseline elevations. No dose adjustment is recommended in patients with moderate hepatic impairment.

PHARMACEUTICAL PARTICULARS

LIST OF EXCIPIENTS
Tablet core:
Pregelatinized starch, Dibasic calcium phosphate dihydrate, Mannitol, Crospovidone, Sodium starch glycolate, Low-substituted hydroxypropyl cellulose (L-HPC, LH-21), Purified water, Colloidal silicon dioxide and Sodium stearyl fumarate,
Tablet coating:
Coating film
Hypromellose (HPMC 2910), Titanium dioxide, Talc, Iron oxide yellow (C.I. No. 77492), Polyethylene glycol (PEG 400), Isopropyl alcohol and Purified water
Clear film
Hypromellose (HPMC 2910), Polyethylene glycol (PEG 400), Isopropyl alcohol and Purified water

INCOMPATIBILITIES
Not applicable

SHELF LIFE
Please refer to expiry date on the blister strip or outer carton.

SPECIAL PRECAUTIONS FOR STORAGE
Store at temperature of not more than 30°C. Protect from light and moisture.

NATURE AND CONTENTS OF CONTAINER
Aluminum foil (silver) - Aluminum foil (gold) blister of 10 tablets; Box of 100 tablets (10 blisters)

DATE OF REVISION:
September 26, 2025

Manufactured by:
UNISON LABORATORIES CO., LTD.
39 Moo 4, Klong Udomcholjorn, Muang Chachoengsao,
Chachoengsao 24000 Thailand

Font size 7